Abstracts tagged "registry"

Abstract Number: 2588 • 2016 ACR/ARHP Annual Meeting
The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort
Leslie R. Harrold^1,2, Heather J. Litman¹, Katherine C. Saunders¹, Kimberly J. Dandreo¹, Bernice Gershenson², Jeffrey D. Greenberg^1,3, Robert Low⁴, Jeffrey Stark⁴, Robert Suruki⁴, Srihari Jaganathan⁴ and Mohamed Yassine⁴, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³NYU School of Medicine, New York, NY, ⁴UCB Pharma, Smyrna, GA
Background/Purpose: To examine the association of cardiovascular, malignant and serious infection events (SIEs) with certolizumab pegol (CZP) use as compared to other TNFi agents in…
Abstract Number: 2618 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in the French Registry Regate (REGISTRY –ROACTEMRA)
Jacques Morel^1,2, Arnaud CONSTANTIN³, Gabriel Baron⁴, Emmanuelle Dernis⁵, Rene-Marc Flipo^6,7, Stephanie Rist Bouillon⁸, Bernard Combe⁹, Jacques-Eric Gottenberg¹⁰, Thierry Schaeverbeke^11,12, Martin Soubrier¹³, Olivier Vittecoq¹⁴, Maxime Dougados¹⁵, Alain Saraux¹⁶, Xavier Mariette¹⁷, Philippe Ravaud¹⁸ and Jean Sibilia¹⁹, ¹Montpellier University Hospital, Montpellier, France, ²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ³Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁴Hôpital Hôtel Dieu, Paris, France, ⁵Service de Rhumatologie, Centre Hospitalier, Le Mans, France, ⁶Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁷Rheumatology, University Hospital, Lille, France, ⁸Rhumatologie, Hopital La Source, La Source, France, ⁹Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Bordeaux University Hospital, Bordeaux, France, ¹²Rheumatology, CHU Bordeaux, Bordeaux, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁵Paris Descartes University, Paris, France, ¹⁶Rheumatology, Brest University Medical School Hospital, Brest, France, ¹⁷Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, ¹⁸Centre d’Épidémiologie Clinique, AP-HP (Assistance Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France, ¹⁹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Observational studies have already reported the risk of serious infections in rheumatoid arthritis (RA) treated with tocilizumab but in limited samples. The aim of…
Abstract Number: 2625 • 2016 ACR/ARHP Annual Meeting
Safety of Multiple Retreatments with Rituximab in Real Life: Long Term Registry Data from 1984 Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Philippe Ravaud², Thomas Bardin³, Alain Cantagrel⁴, Bernard Combe⁵, Maxime Dougados⁶, RENE MARC FLIPO⁷, Olivier Vittecoq⁸, Thierry Schaeverbeke⁹, Isabelle Pane¹⁰, Jean Sibilia¹¹, Xavier Mariette¹² and on behaf of all of the investigators of the AIR registry and of the French Society of Rheumatology , ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hotel Dieu, PARIS, France, ³Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁴Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁵Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Rheumatology, Paris Descartes University, Paris, France, ⁷Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, ⁸INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁹Rheumatology, CHU Bordeaux, Bordeaux, France, ¹⁰Epidemiology, Hotel Dieu, Paris, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: Data are very limited concerning the safety of multiple retreatments with rituximab (RTX) in rheumatoid arthritis in common practice. Methods: This is a multicenter…
Abstract Number: 443 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register
Pongthorn Narongroeknawin¹, Wanruchada Katchamart², Parawee Suwannalai³, Nuntana Kasitanon⁴, Tasanee Kitumnuaypong⁵, Ajanee Mahakkanukrauh⁶ and Boonjing Siripaitoon⁷, ¹Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, ²Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand, ³Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁵Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand, ⁶Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, ⁷Division of Rheumatology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
Background/Purpose: To evaluate long-term efficacy and safety of biological disease modifying antirheumatic drug (bDMARD) in real-life practice and identify risk factors related to remission and drug discontinuation…
Abstract Number: 2744 • 2015 ACR/ARHP Annual Meeting
What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? an Analysis from a Real-World Registry
Rafat Faraawi¹, Raman Joshi², William G Bensen³, Denis Choquette⁴, Wojciech Olsynzynski⁵, Regan Arendse⁵, Maqbool Sheriff⁶, Proton Rahman⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹, Cathy Tkaczyk¹¹ and Brendan Osborne¹¹, ¹McMaster University, Hamilton, ON, Canada, ²William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁵University of Saskatchewan, Saskatoon, ON, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Medicine, Memorial University, St John's, NF, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of TNF inhibitors. A scarcity of data exists on…
Abstract Number: 2938 • 2015 ACR/ARHP Annual Meeting
Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Kichul Ko¹, Alana B. Levine², Russell Griffin³, Olga Dvorkina⁴, Saira Sheikh⁵, Jinoos Yazdany⁶, Richard Furie⁷ and Cynthia Aranow⁸, ¹Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, SUNY Health Science Center at Brooklyn, Brooklyn, NY, ⁵University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ⁸Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: Treating to a target of remission or low disease activity state (LDAS) is an attractive potential therapeutic approach in SLE. Recently, LDAS and remission…
Abstract Number: 382 • 2014 ACR/ARHP Annual Meeting
What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months?
Edward C. Keystone¹, Carter Thorne², Michael Starr³, Jude Rodrigues⁴, Philip Baer⁵, Regan Arendse⁶, J. Antonio Avina-Zubieta⁷, Denis Choquette⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, May Shawi¹⁰, Francois Nantel¹⁰, Allen J Lehman¹¹ and Susan Otawa¹¹, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁵Private Practice, Scarborough, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to optimize symptom control and, when possible, achieve sustained remission. Therefore, identification of clinical signs predicting…
Abstract Number: 365 • 2014 ACR/ARHP Annual Meeting
Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Denis Choquette¹, Dalton Sholter², Isabelle Fortin³, Michael Starr⁴, Carter Thorne⁵, Milton Baker⁶, Regan Arendse⁷, Philip Baer⁸, Michel Zummer⁹, Jude Rodrigues¹⁰, Maqbool Sheriff¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, Allen J Lehman¹⁴, Susan Otawa¹⁴ and May Shawi¹³, ¹Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶University of Victoria, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Scarborough, ON, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Clinical Research and Arthritis Centre, Windsor, ON, Canada, ¹¹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose DAS28 is an important outcome for clinical research and practice assisting with therapeutic decisions. The main contributors to DAS28 are joint tenderness and acute-phase…
Abstract Number: 2496 • 2014 ACR/ARHP Annual Meeting
Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Boulos Haraoui¹, Maqbool Sheriff², Majed Khraishi³, Michael Starr⁴, John Kelsall⁵, Milton Baker⁶, Regan Arendse⁷, Sanjay Dixit⁸, William Bensen⁹, Philip Baer¹⁰, Rafat Faraawi⁸, Emmanouil Rampakakis¹¹, John S. Sampalis¹¹, Susan Otawa¹², Allen J Lehman¹², Francois Nantel¹³ and May Shawi¹³, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶University of Victoria, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ¹⁰Private Practice, Scarborough, ON, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose Early achievement of remission is associated with improved clinical, functional and radiographic outcomes1. Recent recommendations of the Canadian Rheumatology Association dictate that treatment target…
Abstract Number: 2511 • 2014 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologic DMARD Therapy Due to Remission in Patients with Rheumatoid Arthritis in a National Registry
Jose A Gomez-Puerta^1,2, M. Victoria Hernández¹, Fernando Sanchez-Alonso³, Kazuki Yoshida^2,4, Raimon Sanmarti¹, Daniel H Solomon², Juan J Gomez-Reino⁵ and On behalf of BIOBADASER 2.0 study group³, ¹Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, Boston, MA, ³Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁴Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, ⁵Hospital Clinico Universitario at the Universidad de Santiago de Compostela, Santiago, Spain
Background/Purpose: Remission is considered an achievable goal for many patients under biologic therapies. However, currently there is limited information about predictors of discontinuation of biologic…
Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting
Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting
John Kelsall¹, Algis Jovaisas², Proton Rahman³, Dalton Sholter⁴, Michael Starr⁵, William Bensen⁶, Maqbool Sheriff⁷, Wojciech Olszynski⁸, Michel Zummer⁹, Rafat Faraawi¹⁰, Andrew Chow¹¹, Suneil Kapur¹², Emmanouil Rampakakis¹³, John S. Sampalis¹³, Francois Nantel¹⁴, Susan Otawa¹⁵, May Shawi¹⁴ and Allen J Lehman¹⁵, ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ¹²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
Abstract Number: 2371 • 2014 ACR/ARHP Annual Meeting
Efficacy of First Line Biological Monotherapy in RA: Data from the Czech Registry Attra
Herman F. Mann^1,2, Sarka Forejtova³, Katerina Jarosova⁴, Ladislav Senolt⁵, Jakub Zavada⁶, Michal Uher⁷, Karel Hejduk⁷ and Karel Pavelka⁸, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁴Na Slupi 4, Institute of Rheumatology, Prague, Czech Republic, ⁵Na Slupi 4, Revmatologicky ustav, Prague, Czech Republic, ⁶Charles University, Prague, Czech Republic, ⁷Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: The biological disease-modifying anti-rheumatic drugs (bDMARDs) should be used for the treatment of rheumatoid arthritis (RA) in combination with conventional synthetic DMARDs (csDMARDs). However…
Abstract Number: 1931 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Aryeh Fischer³, Jerry A. Molitor⁴ and Virginia D. Steen⁵, ¹Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ³Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁴Rheumatology, University of Minnesota, Minneapolis, MN, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Systemic sclerosis (SSc) related pulmonary hypertension (PH) carries a high mortality and patients with SSc-PH related to restrictive lung disease having an even worse…
Abstract Number: 1760 • 2014 ACR/ARHP Annual Meeting
United Kingdom & Ireland Vasculitis Registry – Cross-Sectional Data on the First 1085 Patients
Jan Sznajd^1,2, Alan D. Salama³, David Jayne⁴, Afzal Chaudhry⁵, Michael Robson⁶, Joe Rosa², Neil Basu⁷, Sarah Moran⁸, Michael Venning⁹, Peter Lanyon¹⁰, Asheesh Sharma¹¹, Mark A. Little¹², Richard Watts¹³ and Raashid Luqmani¹⁴, ¹Jagiellonian University Medical College, Krakow, Poland, ²Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Centre for Nephrology, University College London, London, United Kingdom, ⁴Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁵Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁶King’s College London, London, United Kingdom, ⁷Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ⁸Cork University Hospital, Cork, United Kingdom, ⁹Manchester Royal Infirmary, Manchester, United Kingdom, ¹⁰Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ¹¹University Hospital Aintree Liverpool, Liverpool, United Kingdom, ¹²Trinity College Dublin, Dublin, Ireland, ¹³Department of Rheumatology, Ipswich Hospital NHS Trust, Ipswich, United Kingdom, ¹⁴Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom
Background/Purpose Clinical care and research into systemic vasculitis is hampered by its rarity and its presentation to a wide array of medical specialties. We aimed…
Abstract Number: 844 • 2014 ACR/ARHP Annual Meeting
Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study
Kenneth G. Saag¹, Kevin L. Winthrop², Daniel E. Furst³, Kimberly Alexander⁴, Angelika Jahreis⁵, Carol Chung⁶ and Kurt Oelke⁷, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³University of California at Los Angeles, Los Angeles, CA, ⁴Epidemiology, Genentech, Inc., South San Francisco, CA, ⁵Genentech, South San Francisco, CA, ⁶Genentech, Inc, South San Francisco, CA, ⁷Rheumatic Disease Center, Glendale, WI
Background/Purpose: Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti–TNF therapy (aTNF-IR). Long-term infection risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].